Noopept

From Wikipedia, the free encyclopedia - View original article

Noopept
Noopept.svg
Systematic (IUPAC) name
N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Legal status
  • US: Unscheduled
Identifiers
CAS number157115-85-0 YesY
ATC code?
PubChemCID 180496
ChemSpider157065 N
Chemical data
FormulaC17H22N2O4 
Molecular mass318.367 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Noopept
Noopept.svg
Systematic (IUPAC) name
N-Phenylacetyl-L-prolylglycine ethyl ester
Clinical data
Legal status
  • US: Unscheduled
Identifiers
CAS number157115-85-0 YesY
ATC code?
PubChemCID 180496
ChemSpider157065 N
Chemical data
FormulaC17H22N2O4 
Molecular mass318.367 g/mol
 N (what is this?)  (verify)

Noopept (Russian: Ноопепт; GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester) is a peptide promoted and prescribed in Russia and neighbouring countries as a nootropic. The registered brand name Noopept (Ноопепт) is trademarked by the manufacturer JSC LEKKO Pharmaceuticals. The compound is patented in both the US and Russia with patent of Russian Federation number 2119496, US Patent number 5,439,930 issued 8/8/1995.[1] It is sold as a dietary supplement in the US and as a medication in other countries.

Mechanism of action[edit]

Noopept Box Front
Noopept blister pack

Noopept is not technically a racetam molecule (due to not having a 2-oxo-pyrollidine skeleton),[2] but is generally grouped together in the same category because it shares similar mechanisms of action with racetam family.[3] When compared to traditional racetams, it has been found to be, according to studies, 1000 times more potent than the prototypical racetam drug, piracetam.[4] Since it is a peptide-derived compound, noopept is degraded by enzymes in the GI tract and liver.

References[edit]

  1. ^ PatentGenius.com http://www.patentgenius.com/patent/5439930.html
  2. ^ [unreliable medical source?]http://examine.com/supplements/Noopept/
  3. ^ Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB (1997). "The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine". European Journal of Drug Metabolism and Pharmacokinetics 22 (3): 245–52. doi:10.1007/BF03189814. PMID 9358206. 
  4. ^ Ostrovskaia RU, Gudasheva TA, Voronina TA, Seredenin SB (2002). "[The original novel nootropic and neuroprotective agent noopept]". Eksperimentalnaia i Klinicheskaia Farmakologiia (in Russian) 65 (5): 66–72. PMID 12596521.